F-100 therapeutic milk
Rehabilitation of severe acute malnutrition
Recommendations for use
- Each 114g sachet should be reconstituted with 500 ml of drinking water in order to obtain about 600 ml of F-100 therapeutic milk. The dry extract and energy density of final solution are 190 grams per liter and 100kcal/100ml, respectively.
- Once reconstituted, F-100 therapeutic milk can be kept for 3 hours at room temperature, and up to 16 hours in a refrigerator. Beyond these limits, it becomes unfit for consumption and must be thrown away.
- In the renutrition phase (phase 2), a child suffering from severe acute malnutrition must receive 200 kcal / kg body weight / day, for an average period of 3 weeks. One carton contains sufficient product for the nutritional treatment of 2 children (weighing 5 kg) for a duration of 21 days.
Packaging and conservation
- Primary packaging: F-100 low osmolarity therapeutic milk is delivered in sachets containing 114g of powder, packaged under protective atmosphere; the sachets are air and water tight, and protected from light. Sachets of F-100 can be used up to 24 months after the date of manufacture.
- Secondary packaging: cartons of 90 sachets (net weight : 10.26 kg ; gross weight : 11.58 kg).
- Palletisation by sea: Pallets with 48 cartons (net weight : 492.45 kg ; gross weight : 578.84 kg).
- Where possible, to be stored in a dry, cool area, at a temperature of less than 30°C.
F-100 low osmolarity therapeutic milk was specielly developed for the nutritional rehabilitation of people suffering from severe acute malnutrition, in phase 2 of the treatment protocol drawn up by the World Health Organisation.
This product must be used in therapeutic renutrition centres with medical supervision, and must not be distributed directly to families.
Main characteristics, target population and benefits obtained
Nutriset began developing this product in 1993. F-100 is a therapeutic milk powder to be reconstitutes by diluting with drinking water. It complies with specifications laid down by nutritionists for the care of people suffering from severe acute malnutrition (marasmus / severe emaciation, kwashiorkor / oedematous malnutrition, mixed forms).
As well as skimmed milk powder, F-100 therapeutic milk contains vegetable fat, whey, maltodextrin, sugar and a mineral and vitamin complex. Its low osmolarity formula improves the absorption of nutrients by the organism.
With its caloric density of 100 kcal per 100 ml of reconstituted milk, F-100 is intended to be used in phase 2 of the protocol drawn up by the World Health Organisation, the nutritional recovery phase (for phase 1, designated as the stabilisation phase, F-75 therapeutic is preferred). F-100 milk can be given to children aged from 6 months up.
References
- La prise en charge de la malnutrition sévère : Manuel à l’usage des médecins et autres personnels de santé à des postes d’encadrement (Management of severe malnutrition: a manual for physicians and other senior health workers), OMS, 1999
http://www.who.int/nutrition/publications/severemalnutrition/9241545119/en/index.html - Treatment of malnutrition in refugee camps, Conference by Mike Golden and André Briend; The Lancet, Volume 342, Issue 8867, 7 August 1993, Page 360
http://www.ncbi.nlm.nih.gov/pubmed/8101595 - Comparison of gastric emptying of a solid and a liquid nutritional rehabilitation food
L. Achour, S. Méance and A. Briend
European Journal of Clinical Nutrition, September 2001, Volume 55, Number 9, Pages 769-772
http://www.nature.com/ejcn/journal/v55/n9/abs/1601221a.html - Comparison of the efficacy of a solid ready-to-use food and a liquid, milk-based diet for the rehabilitation of severely malnourished children: a randomized trial El Hadji Issakha Diop, Nicole Idohou Dossou, Marie Madeleine Ndour, André Briend and Salimata Wade
American Journal of Clinical Nutrition, Vol. 78, No. 2, 302-307, August 2003
http://www.ajcn.org/cgi/content/abstract/78/2/302 - WHO guidelines for severe malnutrition: are they feasible in rural African hospitals?
Nadina Karaolis, Debra Jackson, Ann Ashworth, David Sanders, Nonzwakazi Sogaula, David McCoy, Mickey Chopra, Claire Schofield
Archive of Disease in Childhood 2007;92:198-204 doi:10.1136/adc.2005.087346
http://adc.bmj.com/content/92/3/198.abstract
